Developer docs
API playgroundTry for free, no card

Search company profiles

AIS Biotech

Full company profile

uuid003eylg

Namestring
AIS Biotech
Websiteurl
ais-biotech.com
Company typeenum
Private
Founded yearint
2023
Short descriptiontext

AIS Biotech is a privately held Grenoble-based biotech developing glycomimetic-based anti-infectives, with lead candidate GlycoFlu, a universal nasal spray for influenza prevention positioned as a complement to vaccines for general consumers and healthcare providers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersGrenoble, France
HQ citystring
Grenoble
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
glycomimetic anti-infectives, nasal influenza prevention, anti-adhesion therapeutics, biotech R&D services, pathogen decoy molecules
Industry1 code
PRIMARYHLAAAEAF
Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Antiviral Pharmaceuticals / Anti-Infective Therapeutics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1GlycoFlu Product Sales
TypeOne Time License
Description

Revenue from sale of GlycoFlu universal nasal spray product, positioned as a complementary solution to traditional influenza vaccines

ais-biotech.com
Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

AIS Biotech develops glycomimetic-based anti-infective therapeutics that act as molecular decoys to block pathogen adhesion to host cells, bypassing resistance mechanisms. Its lead commercial product, GlycoFlu, is a universal nasal spray providing broad-spectrum protection against all influenza strains without requiring annual reformulation, positioned as a complement to seasonal vaccines. The pipeline is supported by a scalable, eco-friendly bioproduction platform enabling extension to additional viral and bacterial targets.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Universal protection against all influenza strains without annual adaptation
Product and service2 records
1GlycoFlu
CategoryAntiviral Pharmaceuticals / Anti-Infective Therapeutics
Description

GlycoFlu is a universal nasal spray anti-infective that uses glycomimetic decoy molecules to prevent pathogen adhesion to host cells, bypassing resistance mechanisms. It is active against all influenza strains without requiring annual adaptation, and is positioned as a complementary solution to traditional influenza vaccines for general consumers and at-risk populations.

2Bioproduction Platform
CategoryBiotech Manufacturing Platform
Description

A scalable and environmentally sustainable bioproduction platform used to manufacture glycomimetic anti-infective compounds, enabling cost-effective green production and supporting expansion of the pipeline into additional viral and bacterial targets beyond influenza.

No data
Peers8 records
TypeEmerging player
Description

Clinical-stage developer of an intranasal M2SR influenza vaccine; directly comparable mucosal-delivery flu-prevention program targeting universal strain coverage.

TypeEmerging player
Description

Developing oral influenza vaccine alternatives to injectable shots; same needle-free, mucosal-immunity thesis as AIS Biotech's intranasal GlycoFlu, though Vaxart uses a vaccine mechanism.

3Sanofi Pasteur
TypeBroad incumbent
Description

One of the world's largest seasonal influenza vaccine manufacturers; relevant incumbent for GlycoFlu's positioning as a universal complement to traditional flu shots.

TypeBroad incumbent
Description

Pursuing mRNA-based seasonal and pandemic influenza vaccines; a future standard-of-care threat if strain-matched mRNA flu shots displace the unmet need GlycoFlu is built around.

TypeDirect peer
Description

Develops mannoside-based anti-adhesion small molecules to prevent bacterial (notably E. coli) attachment to host cells; the closest mechanistic comparable to AIS Biotech's glycomimetic decoy approach, focused on anti-infective indications.

TypeBroad incumbent
Description

Major influenza vaccine producer with broad respiratory anti-infective portfolio; sets the standard-of-care bar that GlycoFlu must differentiate against.

TypeDirect peer
Description

Developed small-molecule glycomimetic drugs (selectin antagonists) for hematology/oncology; same glycomimetic drug class as AIS Biotech's core chemistry, making it the most direct technology comparable even though application differs. Acquired by Pfizer in 2022.

TypeBroad incumbent
Description

Markets FluMist, the only widely available intranasal influenza vaccine, making it the most directly comparable intranasal flu-prevention product even though delivered via LAIV rather than glycomimetic decoy.

Market position
Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AIS Biotech

Antiviral Pharmaceuticals / Anti-Infective Therapeuticsais-biotech.com

AIS Biotech is a privately held Grenoble-based biotech developing glycomimetic-based anti-infectives, with lead candidate GlycoFlu, a universal nasal spray for influenza prevention positioned as a complement to vaccines for general consumers and healthcare providers.

AIS Biotech firmographics

Firmographics
Name
AIS Biotech
Website
https://ais-biotech.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
1–10 employees
Short description
AIS Biotech is a privately held Grenoble-based biotech developing glycomimetic-based anti-infectives, with lead candidate GlycoFlu, a universal nasal spray for influenza prevention positioned as a complement to vaccines for general consumers and healthcare providers.
Ownership category
akta.pro rank

AIS Biotech industry classification

Industry
Product category
Antiviral Pharmaceuticals / Anti-Infective Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAEAF
Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Glycomimetic anti-infectives
  • Nasal influenza prevention
  • Anti-adhesion therapeutics
  • Biotech R&D services
  • Pathogen decoy molecules

Where AIS Biotech is headquartered

Location

Headquarters

HQ city
Grenoble
HQ country
France
HQ region
Europe

Markets served

AIS Biotech business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. GlycoFlu Product Sales: Revenue from sale of GlycoFlu universal nasal spray product, positioned as a complementary solution to traditional influenza vaccines

Go-to-market motion1 record

AIS Biotech product offering

Product offering

Core offering

AIS Biotech develops glycomimetic-based anti-infective therapeutics that act as molecular decoys to block pathogen adhesion to host cells, bypassing resistance mechanisms. Its lead commercial product, GlycoFlu, is a universal nasal spray providing broad-spectrum protection against all influenza strains without requiring annual reformulation, positioned as a complement to seasonal vaccines. The pipeline is supported by a scalable, eco-friendly bioproduction platform enabling extension to additional viral and bacterial targets.

Differentiator

Problem solved

Functional benefit

Products and services

  • GlycoFlu GlycoFlu is a universal nasal spray anti-infective that uses glycomimetic decoy molecules to prevent pathogen adhesion to host cells, bypassing resistance mechanisms. It is active against all influenza strains without requiring annual adaptation, and is positioned as a complementary solution to traditional influenza vaccines for general consumers and at-risk populations.
  • Bioproduction Platform A scalable and environmentally sustainable bioproduction platform used to manufacture glycomimetic anti-infective compounds, enabling cost-effective green production and supporting expansion of the pipeline into additional viral and bacterial targets beyond influenza.

Quantifiable outcome

  • Universal protection against all influenza strains without annual adaptation

Companies that use AIS Biotech

Customer profile

Segments2 records

Ideal customer profiles2 records

AIS Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

AIS Biotech competitors and assessment

Company assessment

Emerging players

  • FluGen: Clinical-stage developer of an intranasal M2SR influenza vaccine; directly comparable mucosal-delivery flu-prevention program targeting universal strain coverage.
  • Vaxart: Developing oral influenza vaccine alternatives to injectable shots; same needle-free, mucosal-immunity thesis as AIS Biotech's intranasal GlycoFlu, though Vaxart uses a vaccine mechanism.

Broad incumbents

  • Sanofi Pasteur: One of the world's largest seasonal influenza vaccine manufacturers; relevant incumbent for GlycoFlu's positioning as a universal complement to traditional flu shots.
  • Moderna: Pursuing mRNA-based seasonal and pandemic influenza vaccines; a future standard-of-care threat if strain-matched mRNA flu shots displace the unmet need GlycoFlu is built around.
  • GSK: Major influenza vaccine producer with broad respiratory anti-infective portfolio; sets the standard-of-care bar that GlycoFlu must differentiate against.
  • AstraZeneca (FluMist): Markets FluMist, the only widely available intranasal influenza vaccine, making it the most directly comparable intranasal flu-prevention product even though delivered via LAIV rather than glycomimetic decoy.

Direct peers

  • Fimbrion Therapeutics: Develops mannoside-based anti-adhesion small molecules to prevent bacterial (notably E. coli) attachment to host cells; the closest mechanistic comparable to AIS Biotech's glycomimetic decoy approach, focused on anti-infective indications.
  • GlycoMimetics (Pfizer): Developed small-molecule glycomimetic drugs (selectin antagonists) for hematology/oncology; same glycomimetic drug class as AIS Biotech's core chemistry, making it the most direct technology comparable even though application differs. Acquired by Pfizer in 2022.

Market position

Customer concentration

AIS Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AIS Biotech leadership team

Management profile

Number of profiles

Profiles2 records

AIS Biotech funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AIS Biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AIS Biotech

What does AIS Biotech do?

AIS Biotech develops glycomimetic-based anti-infective therapeutics that act as molecular decoys to block pathogen adhesion to host cells, bypassing resistance mechanisms. Its lead commercial product, GlycoFlu, is a universal nasal spray providing broad-spectrum protection against all influenza strains without requiring annual reformulation, positioned as a complement to seasonal vaccines. The pipeline is supported by a scalable, eco-friendly bioproduction platform enabling extension to additional viral and bacterial targets.

Is AIS Biotech a public or private company?

AIS Biotech is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was AIS Biotech founded?

AIS Biotech was founded in 2023. It employs 1 to 10 people.

Where is AIS Biotech based?

AIS Biotech is headquartered in Grenoble, France, in the Europe region.

How does AIS Biotech make money?

One revenue line is on record: glycoFlu Product Sales.

Who are AIS Biotech's main competitors?

Emerging players on record are FluGen and Vaxart. Broad incumbents are Sanofi Pasteur, Moderna, GSK and AstraZeneca (FluMist). Direct peers are Fimbrion Therapeutics and GlycoMimetics (Pfizer).

Does AIS Biotech have an API?

No public API is recorded for AIS Biotech.

What industry is AIS Biotech in?

AIS Biotech's product category is Antiviral Pharmaceuticals / Anti-Infective Therapeutics. Its primary akta.pro industry code is HLAAAEAF, Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales